tradingkey.logo
tradingkey.logo

Immuneering rises as quarterly loss comes in below estimates

ReutersMar 6, 2026 1:19 PM

Shares of therapy developer Immuneering IMRX.O rise 2.6% to $5.01 premarket

Co reports Q4 adj. loss of 18 cents/shr vs analysts’ average estimate of 31 cents/shr – data compiled by LSEG

Co says cash runway expected to fund operations into 2029

IMRX says expanded pancreatic cancer cohort data on track for 1H 2026

Dosing in mid‑stage trial of cancer drugs atebimetinib and Libtayo in lung cancer expected in 2H 2026, per co

Shares up ~199% in 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI